Total body weight

1 paper1 finding

Human trial1

Interventions

1

Dapagliflozin

downin humans1

1 study

Dapagliflozin decreases total body weight in humans (-2.08 kg (95% CI -2.84 to -1.31)).
“TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]”
Human trialinadequate glycemic control on open-label metformin10 mg/d24 wk
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
The Journal of clinical endocrinology and metabolism11 Jan 2012

More on Dapagliflozin

Latest

21 in 12 months

medRxiv6 Oct

Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice

Preprint: cohort study of 743,153 peopleTirzepatide

Journal of the Endocrine Society1 Oct

Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study

Cohort study of 1,028 peopleTirzepatide

Canadian Agency for Drugs and Technologies in Health, Ottawa30 Sep

Tirzepatide (Zepbound): Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease): Reimbursement Recommendation

Systematic review of randomised trialsIndustry & policy

Journal of the International Society of Sports Nutrition21 Sep

Resistance training combined with creatine supplementation: a three-level meta-analysis of multidimensional outcomes from strength enhancement to body composition remodeling

Meta-analysisCreatine

Therapeutic Advances in Reproductive Health18 Sep

The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review

JCEM Case Reports17 Sep

Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome

Case reportInterventions

Diabetes Therapy15 Sep

Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan

Study protocolType 2 diabetes

Genome Medicine4 Sep

A multi-ancestry polygenic risk score for body mass index predicts longitudinal weight change

Cohort study of 158,743 peopleBody mass index

Clinics and Practice26 Aug

Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens

Cohort study of 166 peopleMetformin

Journal of the Endocrine Society24 Aug

Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome

Cohort study of 54,114 peopleTirzepatide